DORIPENEM

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H24N4O6S2
Molecular Weight	420.504
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O

InChI

InChIKey=AVAACINZEOAHHE-VFZPANTDSA-N

InChI=1S/C15H24N4O6S2/c1-6-11-10(7(2)20)14(21)19(11)12(15(22)23)13(6)26-9-3-8(17-5-9)4-18-27(16,24)25/h6-11,17-18,20H,3-5H2,1-2H3,(H,22,23)(H2,16,24,25)/t6-,7-,8+,9+,10-,11-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C15H24N4O6S2
Molecular Weight	420.504
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4364b1-02-johnson.pdf
Curator's Comment: Description was created based on several sources including http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446428/#B1

Doripenem is a synthetic carbapenem that has broad antibacterial potency against aerobic and anaerobic gram-positive and gram-negative bacteria. Doripenem is structurally related to beta-lactam antibiotics and shares the bactericidal mode of action of other β-lactam antibiotics by targeting penicillin-binding proteins (PBPs) to inhibit the biosynthesis of the bacterial cell wall. Doripenem is resistant to hydrolysis by most β-lactamases and is resistant to inactivation by renal dehydropeptidases. Doripenem has many similarities to the other carbapenems, as well as some important differences, such as greater potency against Pseudomonas aeruginosa. It was found to be similar to comparator agents. The most common adverse effects related to doripenem therapy were headache, nausea, diarrhea, rash, and phlebitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 234 Target ID: CHEMBL2354204 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf	Inhibitor 8504		47.6 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Complicated urinary tract infections 12 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf	Curative	Approved 8583	DORIBAX Approved Use Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 2007
Nosocomial pneumonia (NP), including ventilator associated pneumonia (VAP). 2 Sources: http://www.sciencedirect.com/science/article/pii/S0924857913000277	Curative	Withdrawn	DORIBAX Approved Use Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 2007
Complicated intra-abdominal infections 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf	Curative	Approved 8583	DORIBAX Approved Use Indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros and as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Launch Date 2007

C_max

Value	Dose	Analyte	Population
16.87 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.94 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.2 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29746394/	250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
23 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022106s002s005lbl.pdf	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
66.4 mg*h/L Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010	1000 mg 3 times / day multiple, intravenous dose: 1000 mg route of administration: intravenous experiment type: multiple co-administered:	DORIPENEM serum	Homo sapiens population: unhealthy age: sex: UNKNOWN food status: UNKNOWN
47.1 mg*h/L Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010	500 mg 3 times / day multiple, intravenous dose: 500 mg route of administration: intravenous experiment type: multiple co-administered:	DORIPENEM serum	Homo sapiens population: unhealthy age: sex: UNKNOWN food status: UNKNOWN
52.98 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
70.64 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29746394/	250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
36.3 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022106s002s005lbl.pdf	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
2.4 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010	1000 mg 3 times / day multiple, intravenous dose: 1000 mg route of administration: intravenous experiment type: multiple co-administered:	DORIPENEM serum	Homo sapiens population: unhealthy age: sex: UNKNOWN food status: UNKNOWN
2.2 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01401010	500 mg 3 times / day multiple, intravenous dose: 500 mg route of administration: intravenous experiment type: multiple co-administered:	DORIPENEM serum	Homo sapiens population: unhealthy age: sex: UNKNOWN food status: UNKNOWN
2.93 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.04 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28920154/	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.91 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29746394/	250 mg single, intravenous dose: 250 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022106s002s005lbl.pdf	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
91.9% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022106s002s005lbl.pdf	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		DORIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 g 3 times / day multiple, intravenous Highest studied dose Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/27298719	unhealthy, 24 years (rangeL 21–37 years) Health Status: unhealthy Age Group: 24 years (rangeL 21–37 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/27298719	Disc. AE: Transaminases increased, Allergic reaction... Other AEs: Leukopenia, Diarrhea... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Allergic reaction (1 patient) Other AEs: Leukopenia (1 patient) Diarrhea (11 patient) Nausea (9 patients) Vomiting (9 patients) Headache (6 patients) Oral candidiasis (3 patients) Rash (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/27298719
500 mg 3 times / day steady, intravenous Recommended Dose: 500 mg, 3 times / day Route: intravenous Route: steady Dose: 500 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf	unhealthy, 54 years (range: 18-90 years) Health Status: unhealthy Age Group: 54 years (range: 18-90 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf	Disc. AE: Nausea, Vulval mycotic infection... AEs leading to discontinuation/dose reduction: Nausea (0.2%) Vulval mycotic infection (0.1%) Rash (0.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf
5 mg/kg single, intravenous Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/26014957	unknown, <8 weeks Health Status: unknown Age Group: <8 weeks Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26014957	Other AEs: Anemia neonatal, Hypoalbuminemia... Other AEs: Anemia neonatal (3 patients) Hypoalbuminemia (3 patients) Hyperglycemia (2 patients) Peripheral edema (1 patient) Patent ductus arteriosus (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/26014957
8 mg/kg single, intravenous Dose: 8 mg/kg Route: intravenous Route: single Dose: 8 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/26014957	unknown, >8 weeks <44 weeks Health Status: unknown Age Group: >8 weeks <44 weeks Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26014957	Other AEs: Anemia neonatal, Peripheral edema... Other AEs: Anemia neonatal (1 patient) Peripheral edema (1 patient) Dermatitis diaper (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/26014957

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 2438 inducer 440	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 CYP2E1 1060 CYP3A4/5 296 CYP4A11 21	CYP450 59 P-gp 2052	CYP1A2 832 CYP2B6 669 CYP2C19 329 CYP3A4/5 133 UGT1A1 78

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP4A11 25	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	no
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely
CYP2C19 2141	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely
CYP3A4/5 357	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely
UGT1A1 303	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page=15 Page: 15.0	unlikely

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP450 59	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf#page13 Page: 13.0	no
P-gp 2052	substrate 4014 Sources: https://doi.org/10.1016/j.ijantimicag.2011.11.019 Page: 2.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022106s000_MedR_P8.pdf#page=10 Page: 10.0

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA006UL2	https://www.aablocks.com/goods/Goods/detail?id=AA006UL2
Aaron Chemicals	AR006VCU	http://www.aaronchem.com/148016-81-3
abcr GmbH	AB452160	http://www.abcr.com/shop/en/AB452160
Achemo Scientific Limited	AC-66571	http://www.achemo.com/search/?Keyword= 148016-81-3
Achemtek	0104-012333	http://www.achemtek.com/364622-82-2
Active Biopharma	ABP000725	http://www.activebiopharma.com/364622-82-2
Adooq BioScience	A12818	https://www.adooq.com/doripenem.html
AHH Chemical co.,ltd	MT-50713	http://www.ahhchemical.com/product/MT-50713.html
Angene	AGN-PC-0Q17TG	http://www.angenechemical.com/productshow/AGN-PC-0Q17TG.html
ApexBio Technology	A2036	http://www.apexbt.com/doripenem-hydrate.html
ApexBio Technology	B1076	http://www.apexbt.com/doripenem.html
Aurora Fine Chemicals LLC	A30.257.818	http://online.aurorafinechemicals.com/info?ID=A30.257.818
AvaChem Scientific	2211	http://www.avachem.com/productSearch.asp?2211
BioCrick	BCC4094	http://www.biocrick.com/Doripenem-BCC4094.html
BLD Pharm	BD31996	http://www.bldpharm.com/products/148016-81-3.html
Chem Scene	CS-2075	http://www.chemscene.com/148016-81-3.html
ChemMol	49401510	http://www.chemmol.com/chemmol/49401510.html
ChemMol	99046355	http://www.chemmol.com/chemmol/99046355.html
Chemspace	CSSB00000055739	https://chem-space.com/CSSB00000055739
Clearsynth	CS-O-01336	http://www.clearsynth.com/en/CSO01336.html
CSNpharm	CSN16169	https://www.csnpharm.com/products/doripenem.html
eNovation Chemicals	D320169	http://www.enovationchem.com/productDetails.asp?productID=D320169
Glentham Life Sciences	GA9212	http://www.glentham.com/products/product/GA9212/
Hefei Hirisun Pharmatech Co., Ltd	HR131453	http://hirisunpharm.com/148016-81-3.html
iChemical	EBD29332	http://www.ichemical.com/products/148016-81-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN01314809	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01314809
Matrix Scientific	146744	https://www.matrixscientific.com/146744.html
MedChem Express	HY-B0187	https://www.medchemexpress.com/doripenem.html
MuseChem	I001815	https://www.musechem.com/product/I001815.html
OChem	7587	http://www.ocheminc.com/index.php?act=psearch&pid=016D813
Parchem	28774	http://www.parchem.com/chemical-supplier-distributor/Doripenem-018774.aspx
Renno Tech	RL01870	http://www.rennotech.com/product_show.asp?id=2119
Selleck Chemicals	S5531	http://www.selleckchem.com/products/doripenem.html
Smolecule	S560427	https://www.smolecule.com/products/s560427
TCI (Tokyo Chemical Industry)	D5249	http://www.tcichemicals.com/eshop/en/us/commodity/D5249/index.html
THE BioTek	bt-288875	https://www.thebiotek.com/product/others/bt-288875

PubMed

Title	Date	PubMed
Update on the treatment of Pseudomonas aeruginosa pneumonia.	2009-08	19520717
Doripenem-induced intertriginous drug eruption as a mild form of AGEP.	2009-08	19453777
Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa.	2009-08	19394788
Doripenem.	2009-07-15	19527173
Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.	2009-07	19553404
Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species.	2009-07	19398458
An analysis of current pharmaceutical industry practices for making clinical trial results publicly accessible.	2009-07	19348964
Doripenem: position in clinical practice.	2009-06	19485791
Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.	2009-06	19369268
Doripenem: antimicrobial profile and clinical potential.	2009-04	19302929
Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).	2009-04	19302928
In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.	2009-04	19302927
Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.	2009-04	19249182
Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.	2009-04	19249180
Activity of a novel carbapenem, doripenem, against anaerobic pathogens.	2009-04	19249176
Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.	2009-04	19249175
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA.	2009-03	19155227
Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.	2009-03	19095418
Monte Carlo simulation for evaluation of the efficacy of carbapenems and new quinolones against ESBL-producing Escherichia coli.	2009-02	19280294
New antibiotics for healthcare-associated pneumonia.	2009-02	19199191
In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.	2009-02	18977642
Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.	2009-01	19243706
Management of severe abdominal infections.	2009-01	19149697
Doripenem: a new addition to the carbapenem class of antimicrobials.	2009-01	19149693
Current treatment of pseudomonal infections in the elderly.	2009	19552489
Current status of newer carbapenems.	2009	19199922
Effects of treatment with antimicrobial agents on the human colonic microflora.	2008-12	19337440
Gateways to clinical trials. December 2008.	2008-12	19271026
New developments in carbapenems.	2008-12	19076841
What's new and not so new on the antimicrobial horizon?	2008-12	19040463
Stability of doripenem in vitro in representative infusion solutions and infusion bags.	2008-11	19108795
Current status of newer antiinfectives.	2008-11	18991803
Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06.	2008-11	18819979
New antibiotic agents for bloodstream infections.	2008-11	18723329
Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation.	2008-11	18703305
Lucasti et al in the May 2008 issue of Clinical Therapeutics.	2008-10	19014850
Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid.	2008-08	18709540
Compatibility of doripenem with other drugs during simulated Y-site administration.	2008-07-01	18574017
Doripenem: a new carbapenem.	2008-07	18717294
Doripenem (Doribax): the newest addition to the carbapenems.	2008-07	18628935
New drugs08, part 2.	2008-07	18580663
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.	2008-07	18549664
Susceptibility of clinical isolates of Pseudomonas aeruginosa in the Northern Kyushu district of Japan to carbapenem antibiotics, determined by an integrated concentration method: evaluation of the method based on Monte Carlo simulation.	2008-06	18574662
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.	2008-05	18555934
[Clinical examination of doripenem for infectious diseases in gynecological and associated fields].	2008-04	18669418
Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia.	2008-04	18498921
[In-vitro activity of panipenem against clinical isolates in 2006].	2008-02	18536215
Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use.	2008	18983709
Doripenem: a review of its use in the treatment of bacterial infections.	2008	18778123
An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?	2008	18495060

Patents

Sample Use Guides

In Vivo Use Guide

500 mg administered every 8 hours by intravenous infusion over one hour in patients ≥18 years of age; for complicated intra-abdominal infection 5–14 days, for complicated UTI, including pyelonephritis 10 days.

Route of Administration: Intravenous

In Vitro Use Guide

HardyDisk™ Doripenem Antimicrobial Susceptibility Test Disks are used for semi-quantitative in vitro susceptibility testing by the agar diffusion test procedure (Kirby-Bauer) of rapidly growing and certain fastidious bacterial pathogens. The concentration of doripenem 10ug has been shown to be active against most isolates of the following microorganisms both in vitro and in clinical infections: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Streptococcus constellatus, Streptococcus intermedius

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:17:36 GMT 2025` Edited by `admin` on `Mon Mar 31 18:17:36 GMT 2025`
Record UNII	BHV525JOBH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DORIBAX

Preferred Name

English

DORIPENEM

Official Name

English

DORIPENEM [EMA EPAR]

Common Name

English

DORIPENEM [MART.]

Common Name

English

doripenem [INN]

Common Name

English

DORIPENEM [USAN]

Common Name

English

1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 3-(((3S,5S)-5-(((AMINOSULFONYL)AMINO)METHYL)-3-PYRROLIDINYL)THIO)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-, (4R,5S,6S)-

Common Name

English

(+)-(4R,5S,6S)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-3-(((3S,5S)-5-((SULFAMOYLAMINO)METHYL)-3-PYRROLIDINYL)THIO)-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID

Systematic Name

English

DORIPENEM [VANDF]

Common Name

English

DORIPENEM [ORANGE BOOK]

Common Name

English

Doripenem [WHO-DD]

Common Name

English

S-4661

Code

English

DORIPENEM [MI]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000011294